1404 related articles for article (PubMed ID: 28334939)
1. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
[TBL] [Abstract][Full Text] [Related]
2. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
3. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
[TBL] [Abstract][Full Text] [Related]
4. Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases.
Gomperts SN; Locascio JJ; Makaretz SJ; Schultz A; Caso C; Vasdev N; Sperling R; Growdon JH; Dickerson BC; Johnson K
JAMA Neurol; 2016 Nov; 73(11):1334-1341. PubMed ID: 27654968
[TBL] [Abstract][Full Text] [Related]
5. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
[TBL] [Abstract][Full Text] [Related]
6. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.
Schwarz AJ; Yu P; Miller BB; Shcherbinin S; Dickson J; Navitsky M; Joshi AD; Devous MD; Mintun MS
Brain; 2016 May; 139(Pt 5):1539-50. PubMed ID: 26936940
[TBL] [Abstract][Full Text] [Related]
7. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
[TBL] [Abstract][Full Text] [Related]
8. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
[TBL] [Abstract][Full Text] [Related]
9. Regional brain hypometabolism is unrelated to regional amyloid plaque burden.
Altmann A; Ng B; Landau SM; Jagust WJ; Greicius MD;
Brain; 2015 Dec; 138(Pt 12):3734-46. PubMed ID: 26419799
[TBL] [Abstract][Full Text] [Related]
10. Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease.
Schöll M; Ossenkoppele R; Strandberg O; Palmqvist S; ; Jögi J; Ohlsson T; Smith R; Hansson O
Brain; 2017 Sep; 140(9):2286-2294. PubMed ID: 29050382
[TBL] [Abstract][Full Text] [Related]
11. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
Betthauser TJ; Koscik RL; Jonaitis EM; Allison SL; Cody KA; Erickson CM; Rowley HA; Stone CK; Mueller KD; Clark LR; Carlsson CM; Chin NA; Asthana S; Christian BT; Johnson SC
Brain; 2020 Jan; 143(1):320-335. PubMed ID: 31886494
[TBL] [Abstract][Full Text] [Related]
12. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study.
Wu KY; Liu CY; Chen CS; Chen CH; Hsiao IT; Hsieh CJ; Lee CP; Yen TC; Lin KJ
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1067-76. PubMed ID: 26739329
[TBL] [Abstract][Full Text] [Related]
13. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy.
Passamonti L; Vázquez Rodríguez P; Hong YT; Allinson KS; Williamson D; Borchert RJ; Sami S; Cope TE; Bevan-Jones WR; Jones PS; Arnold R; Surendranathan A; Mak E; Su L; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB
Brain; 2017 Mar; 140(3):781-791. PubMed ID: 28122879
[TBL] [Abstract][Full Text] [Related]
14. Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment.
King-Robson J; Wilson H; Politis M;
J Alzheimers Dis; 2021; 82(2):541-560. PubMed ID: 34057079
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
Pascoal TA; Benedet AL; Tudorascu DL; Therriault J; Mathotaarachchi S; Savard M; Lussier FZ; Tissot C; Chamoun M; Kang MS; Stevenson J; Massarweh G; Guiot MC; Soucy JP; Gauthier S; Rosa-Neto P
Brain; 2021 Dec; 144(11):3517-3528. PubMed ID: 34515754
[TBL] [Abstract][Full Text] [Related]
16. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
17. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.
Okamura N; Furumoto S; Fodero-Tavoletti MT; Mulligan RS; Harada R; Yates P; Pejoska S; Kudo Y; Masters CL; Yanai K; Rowe CC; Villemagne VL
Brain; 2014 Jun; 137(Pt 6):1762-71. PubMed ID: 24681664
[TBL] [Abstract][Full Text] [Related]
18. Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.
Yew B; Nation DA;
Brain; 2017 Jul; 140(7):1987-2001. PubMed ID: 28575149
[TBL] [Abstract][Full Text] [Related]
19. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.
Pontecorvo MJ; Devous MD; Kennedy I; Navitsky M; Lu M; Galante N; Salloway S; Doraiswamy PM; Southekal S; Arora AK; McGeehan A; Lim NC; Xiong H; Truocchio SP; Joshi AD; Shcherbinin S; Teske B; Fleisher AS; Mintun MA
Brain; 2019 Jun; 142(6):1723-1735. PubMed ID: 31009046
[TBL] [Abstract][Full Text] [Related]
20. Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults.
Buckley RF; Mormino EC; Rabin JS; Hohman TJ; Landau S; Hanseeuw BJ; Jacobs HIL; Papp KV; Amariglio RE; Properzi MJ; Schultz AP; Kirn D; Scott MR; Hedden T; Farrell M; Price J; Chhatwal J; Rentz DM; Villemagne VL; Johnson KA; Sperling RA
JAMA Neurol; 2019 May; 76(5):542-551. PubMed ID: 30715078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]